What we're reading, January 11, 2016: drug shortages in the emergency departments have quadrupled since 2008; the government has done little to verify people enrolling after Obamacare deadline under special enrollment categories; and Pfizer increased the prices of 100 drugs.
Since 2008, drug shortages in US emergency departments have quadrupled, according to researchers at George Washington University. Some of the reasons for these shortages are because manufacturers can’t meet demands or have simply stopped making the drugs, reported United Press International. Drug shortages may have declined from 2002 to 2007, but increased 435% between 2008 and 2014.
As the Obama administration pushes for more people to sign up for insurance under the Affordable Care Act, including adding more than 30 “special enrollment” categories, insurers are concerned more people enrolling after the deadline will drive up costs. According to The New York Times, the federal government has done little to verify the eligibility of late enrollees for these special enrollment categories. Insurers, like Aetna, highlighted the issue that with little verification, individuals can wait until they are sick and drop coverage after they receive healthcare services “making the annual open enrollment period meaningless.”
During 2015 there was increased scrutiny on rising drug prices, but that didn’t stop Pfizer from raising US prices for more than 100 drugs. Reuters reported that there were no price reductions and that some drugs—Dilantin, Menest, Nitrostat, Tykosyn, and Tygacil—were all increased by 20%. Lyrica’s price increased 9.4%, while the breast cancer drug Ibrance, which already cost $118,200 a year received a 5% increase.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More